Artivion Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company offers BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and E-vita Open Plus and E-vita Open Neo. It also provides E-xtra design engineering systems for the treatment of aortic vascular diseases; E-nside, an off-the-shelf stent graft for the treatment …
Over the last 12 months, insiders at Artivion, Inc. have bought $0 and sold $5.41M worth of Artivion, Inc. stock.
On average, over the past 5 years, insiders at Artivion, Inc. have bought $423,204 and sold $2.9M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 15,000 shares for transaction amount of $260,400 was made by SEMEDO ANTHONY B. (director) on 2021‑11‑29.
2024-10-01 | Sale | VP, Chief Accounting Officer | 12,430 0.0302% | $26.18 | $325,415 | +0.53% | ||
2024-08-26 | Sale | SVP, General Counsel | 3,167 0.0076% | $26.55 | $84,096 | -1.26% | ||
2024-08-16 | Sale | VP, Human Resources | 9,420 0.0228% | $25.31 | $238,434 | -0.32% | ||
2024-08-15 | Sale | SVP, General Counsel | 2,383 0.0059% | $25.76 | $61,393 | 0.00% | ||
2024-08-13 | Sale | director | 9,709 0.0232% | $24.99 | $242,628 | 0.00% | ||
2024-05-10 | Sale | SVP, General Counsel | 1,250 0.003% | $23.42 | $29,275 | +7.44% | ||
2024-05-09 | Sale | SVP, General Counsel | 979 0.0024% | $23.79 | $23,286 | +7.92% | ||
2024-03-20 | Sale | SVP, Clinical & MD Affair | 2,183 0.0052% | $20.39 | $44,511 | +15.02% | ||
2024-03-15 | Sale | VP Regulatory | 1,462 0.0036% | $20.00 | $29,240 | +20.42% | ||
2024-03-14 | Sale | VP Regulatory | 3,994 0.0097% | $20.00 | $79,880 | +18.37% | ||
2024-03-12 | Sale | VP, Human Resources | 5,000 0.0121% | $19.94 | $99,720 | +18.86% | ||
2024-03-05 | Sale | President & CEO | 13,996 0.0343% | $18.72 | $262,037 | +27.53% | ||
2024-03-05 | Sale | SVP, General Counsel | 2,380 0.0058% | $18.72 | $44,559 | +27.53% | ||
2024-03-05 | Sale | Chief Commercial Officer | 2,022 0.005% | $18.72 | $37,856 | +27.53% | ||
2024-03-05 | Sale | VP, Chief Accounting Officer | 1,152 0.0028% | $18.72 | $21,568 | +27.53% | ||
2024-03-05 | Sale | SVP, Clinical & MD Affair | 1,506 0.0037% | $18.72 | $28,195 | +27.53% | ||
2024-03-05 | Sale | VP, Human Resources | 1,157 0.0028% | $18.72 | $21,661 | +27.53% | ||
2024-03-05 | Sale | VP Regulatory | 1,160 0.0028% | $18.72 | $21,718 | +27.53% | ||
2024-03-05 | Sale | VP, Quality | 1,157 0.0028% | $18.72 | $21,662 | +27.53% | ||
2024-03-01 | Sale | SVP, Clinical & MD Affair | 1,506 0.0036% | $18.72 | $28,195 | +24.08% |
Mackin James P | President & CEO | 706038 1.6853% | $29.64 | 4 | 16 | +33.26% |
Davis John E | Chief Commercial Officer | 165690 0.3955% | $29.64 | 2 | 16 | +28.47% |
SEMEDO ANTHONY B. | director | 34159 0.0815% | $29.64 | 1 | 1 | +9.19% |
LEE DAVID ASHLEY | Executive VP, COO & CFO | 347217 0.8288% | $29.64 | 2 | 19 | +25.04% |
Bullock James | director | 34023 0.0812% | $29.64 | 1 | 0 | +47.76% |
BlackRock | $142.64M | 16.15 | 6.74M | -1.51% | -$2.19M | <0.01 | |
Macquarie Group | $59.21M | 6.71 | 2.8M | -2.63% | -$1.6M | 0.05 | |
Perceptive Advisors | $56.48M | 6.4 | 2.67M | +186.57% | +$36.77M | 0.04 | |
The Vanguard Group | $56.39M | 6.39 | 2.66M | +1.29% | +$719,059.12 | <0.01 | |
Morgan Stanley | $49.44M | 5.6 | 2.34M | -1.86% | -$936,478.50 | <0.01 |